The firm was able to maintain a minimum closing bid price of at least $1 per share for at least 10 consecutive business days.
In December, the company effected a 1-for-10 reverse stock split in order to help regain compliance with Nasdaq's minimum closing bid requirement.
The firm recently enacted a 1-for-5 reverse stock split to help its shares meet the minimum bid price requirement for listing on the market.
As of Nov. 21 the company evidenced a closing bid price of its common stock in excess of the $1 minimum requirement for at least 10 consecutive trading days.
The molecular testing firm, which received a notice of potential delisting in January, said it may regain compliance through a reverse stock split, if necessary.
The molecular diagnostics company has been given 60 days to demonstrate that it's in compliance with TSX listing requirements.
The firm, which was previously listed on the over-the-counter market, anticipates $8.5 million in net proceeds from the offering.
The Australian firm regained compliance on a rule for a minimum $1 bid on its shares, while its deadline to meet a rule for a minimum $2.5 million in shareholders' equity was extended.
NEW YORK (GenomeWeb News) – NeoGenomics has been approved to list its shares on the Nasdaq Capital Market, the Ft. Myers, Fla.-based firm said today.
NEW YORK (GenomeWeb News) – Trovagene announced late on Tuesday the pricing of a public offering of 1.15 million units and said that its shares will begin trading on the Nasdaq Capital Market today under ticker symbol "TROV".
23andMe and Airbnb have partnered to offer "heritage travel," according to Venture Beat.
China may include regulations protecting genes and embryos in its update of its civil code, Nature News reports.
In Nature this week: exome sequence analysis of individuals with type 2 diabetes, genomic prediction of maize yield across environments, and more.
NPR reports on efforts to engineer bacteriophages to destroy antibiotic-resistance bacteria.